Literature DB >> 17625608

Common deleted genes in the 5q- syndrome: thrombocytopenia and reduced erythroid colony formation in SPARC null mice.

S Lehmann1, J O'Kelly, S Raynaud, S E Funk, E H Sage, H P Koeffler.   

Abstract

The commonly deleted region (CDR) for the 5q- syndrome has been identified as a 1.5-megabase interval on human chromosome 5q32. We studied, by real-time reverse-transcription (RT)-PCR, the expression of 33 genes within the CDR that are known to be expressed in CD34+ hematopoietic stem cells. Genes in the 5q- samples that showed the most pronounced decrease in expression compared to non-5q- samples were: solute carrier family 36, member 1 (SLC36A1; 89% downregulated), Ras-GTPase-activating protein SH3 domain-binding (G3BP; 79%), antioxidant protein 1 (ATOX1; 76%), colony-stimulating factor-1 receptor precursor (CSF1R; 76%), ribosomal protein S14 (RPS14; 74%), platelet-derived growth factor receptor-beta (PDGFRB; 73%), Nef-associated factor 1 (TNIP1; 72%), secreted protein, acidic and rich in cysteine (SPARC; 71%), annexin VI (ANAX6; 69%), NSDT (66%) and TIGD (60%). We further studied the hematopoietic system in SPARC-null mice. These mice showed significantly lower platelet counts compared to wild-type animals (P=0.008). Although hemoglobin, hematocrit and mean corpuscular volume (MCV) were lower in mice lacking SPARC, differences were not statistically significant. SPARC-null mice showed a significantly impaired ability to form erythroid burst-forming units (BFU-E). However, no significant differences were found in the formation of erythroid colony-forming units (CFU-E), granulocyte/monocyte colony-forming units (CFU-GM) or megakaryocyte colony-forming units (CFU-Mk) in these animals. We conclude that many of the genes within the CDR associated with the 5q- syndrome exhibit significantly decreased expression and that SPARC, as a potential tumor suppressor gene, may play a role in the pathogenesis of this disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17625608     DOI: 10.1038/sj.leu.2404852

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  20 in total

Review 1.  Molecular dissection of the 5q deletion in myelodysplastic syndrome.

Authors:  Benjamin L Ebert
Journal:  Semin Oncol       Date:  2011-10       Impact factor: 4.929

2.  The 5q- syndrome: biology and treatment.

Authors:  Eric Padron; Rami Komrokji; Alan F List
Journal:  Curr Treat Options Oncol       Date:  2011-12

Review 3.  Therapy-related myeloid neoplasms: when genetics and environment collide.

Authors:  Megan E McNerney; Lucy A Godley; Michelle M Le Beau
Journal:  Nat Rev Cancer       Date:  2017-08-24       Impact factor: 60.716

Review 4.  Engineering mouse models with myelodysplastic syndrome human candidate genes; how relevant are they?

Authors:  Stephanie Beurlet; Christine Chomienne; Rose Ann Padua
Journal:  Haematologica       Date:  2012-10-12       Impact factor: 9.941

5.  IFATS collection: Combinatorial peptides identify alpha5beta1 integrin as a receptor for the matricellular protein SPARC on adipose stromal cells.

Authors:  Jing Nie; Benny Chang; Dmitry O Traktuev; Jessica Sun; Keith March; Lawrence Chan; E Helene Sage; Renata Pasqualini; Wadih Arap; Mikhail G Kolonin
Journal:  Stem Cells       Date:  2008-06-26       Impact factor: 6.277

6.  MicroRNA-584 and the protein phosphatase and actin regulator 1 (PHACTR1), a new signaling route through which transforming growth factor-β Mediates the migration and actin dynamics of breast cancer cells.

Authors:  Nadège Fils-Aimé; Meiou Dai; Jimin Guo; Mayada El-Mousawi; Bora Kahramangil; Jean-Charles Neel; Jean-Jacques Lebrun
Journal:  J Biol Chem       Date:  2013-03-11       Impact factor: 5.157

7.  Chromosome 5q deletion is extremely rare in patients with myelofibrosis.

Authors:  Koichi Takahashi; Jorge Cortes; Sherry Pierce; Lynne Abruzzo; Hagop Kantarjian; Srdan Verstovsek
Journal:  Leuk Res       Date:  2013-02-04       Impact factor: 3.156

8.  Original Research: A case-control genome-wide association study identifies genetic modifiers of fetal hemoglobin in sickle cell disease.

Authors:  Li Liu; Alexander Pertsemlidis; Liang-Hao Ding; Michael D Story; Martin H Steinberg; Paola Sebastiani; Carolyn Hoppe; Samir K Ballas; Betty S Pace
Journal:  Exp Biol Med (Maywood)       Date:  2016-03-27

9.  A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide.

Authors:  Sheng Wei; Xianghong Chen; Kathy Rocha; P K Epling-Burnette; Julie Y Djeu; Qing Liu; John Byrd; Lubomir Sokol; Nick Lawrence; Roberta Pireddu; Gordon Dewald; Ann Williams; Jaroslaw Maciejewski; Alan List
Journal:  Proc Natl Acad Sci U S A       Date:  2009-05-26       Impact factor: 11.205

10.  A p53-dependent mechanism underlies macrocytic anemia in a mouse model of human 5q- syndrome.

Authors:  Jillian L Barlow; Lesley F Drynan; Duncan R Hewett; Luke R Holmes; Silvia Lorenzo-Abalde; Alison L Lane; Helen E Jolin; Richard Pannell; Angela J Middleton; See Heng Wong; Alan J Warren; James S Wainscoat; Jacqueline Boultwood; Andrew N J McKenzie
Journal:  Nat Med       Date:  2009-11-22       Impact factor: 53.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.